Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

Inclusion Criteria: * A patient suffering from ocular hypertension, XFG or POAG and needs treatment in both eyes * Patient is at least 18 years * Patient is able and willing to participate in the study for the whole duration of the follow up and is willing to sign the consent form. Exclusion Criteria: * Unwilling to sign informed consent; * Younger than 18 years old; * Ocular condition that are of safety concern and that can interfere with the study results; * Visual field defects with an MD value above -15dB on either eye on Humphrey (or the equivalent in Octopus) and/or threatening fixation * Contact lens wearer; * Closed/barely open anterior chamber angles or history of acute angle closure on either eye as assessed by gonioscopy; * Ocular surgery (other than glaucoma surgery) or argon laser trabeculoplasty within the past three months on either eye; * Glaucoma surgery within the past 6 months on either eye; * Ocular inflammation/infection occurring within three months prior to pre-trial visit on either eye; * Concomitant topical ocular medication that can interfere with study medication on either eye; * Known hypersensitivity to any component of the trial drug solutions; * Other abnormal condition or symptom preventing the patient from entering the trial, according to the Investigator's judgement; * Refractive surgery patients at any time; * Women who are pregnant, are of childbearing potential and are not using adequate contraception or are nursing; * Inability to adhere to treatment/visit plan; * Have participated in any other Interventional clinical trial (i.e., requiring informed consent) involving an investigational drug within one month prior to pre-trial visit. * History of COPD, asthma or heart failure